Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (22)
Keerti Vishwakarma, Rajdeep Dey & Hardik Bhatt. (2023) Telomerase: A prominent oncological target for development of chemotherapeutic agents. European Journal of Medicinal Chemistry 249, pages 115121.
Crossref
Crossref
Persefoni Fragkiadaki, Elisavet Renieri, Katerina Kalliantasi, Elisavet Kouvidi, Evita Apalaki, Elena Vakonaki, Charalampos Mamoulakis, Demetrios Spandidos & Aristidis Tsatsakis. (2022) Τelomerase inhibitors and activators in aging and cancer: A systematic review. Molecular Medicine Reports 25:5.
Crossref
Crossref
Zhi-Gang Sun, Zhi-Na Li, Jin-Mai Zhang, Xiao-Yan Hou, Stacy Mary Yeh & Xin Ming. (2022) Recent Developments of Flavonoids with Various Activities. Current Topics in Medicinal Chemistry 22:4, pages 305-329.
Crossref
Crossref
Maria Bousali & Timokratis Karamitros. (2022) Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma. Microorganisms 10:2, pages 253.
Crossref
Crossref
Giulia Culletta, Mario Allegra, Anna Maria Almerico, Ignazio Restivo & Marco Tutone. (2022) In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity. Pharmaceuticals 15:1, pages 82.
Crossref
Crossref
Niina Dubik & Sabine Mai. (2020) Lamin A/C: Function in Normal and Tumor Cells. Cancers 12:12, pages 3688.
Crossref
Crossref
Marta Dratwa, Barbara Wysoczańska, Piotr Łacina, Tomasz Kubik & Katarzyna Bogunia-Kubik. (2020) TERT—Regulation and Roles in Cancer Formation. Frontiers in Immunology 11.
Crossref
Crossref
Maciej Baginski & Katarzyna Serbakowska. (2020) In silico design of telomerase inhibitors. Drug Discovery Today 25:7, pages 1213-1222.
Crossref
Crossref
Luan Wen, Changzhi Zhao, Jun Song, Linyuan Ma, Jinxue Ruan, Xiaofeng Xia, Y. Eugene Chen, Jifeng Zhang, Peter X. Ma & Jie Xu. (2020) CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells. International Journal of Molecular Sciences 21:2, pages 653.
Crossref
Crossref
Sirui Ma, Soumon Rudra, Jian L Campian, Sonika Dahiya, Gavin P Dunn, Tanner Johanns, Michael Goldstein, Albert H Kim & Jiayi Huang. (2020) Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances 2:1.
Crossref
Crossref
Ying Liu, Zhi Li, Xinyue Tang, Min Li & Feng Shi. (2019) Association between hTERT Polymorphisms and Female Papillary Thyroid Carcinoma. Recent Patents on Anti-Cancer Drug Discovery 14:3, pages 268-279.
Crossref
Crossref
Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, Kohei Fukuoka, Yuko Matsushita, Yoshiko Maida, Mami Yasukawa, Mitsuhiro Hayashi, Raku Shinkyo, Kiyomi Kikuchi, Akitake Mukasa, Ryo Nishikawa, Kenji Tamura, Yoshitaka Narita, Akinobu Hamada, Kenkichi Masutomi & Koichi Ichimura. (2019) Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Science 110:7, pages 2247-2257.
Crossref
Crossref
Karollyne da Silva Morais, Daniel da Silva Arcanjo, Giselle Pinto Faria Lopes, Guilherme Guimarães Silva, Tales Henrique Andrade Mota, Thiago Rodrigues Gabriel, Doralina do Amaral Rabello Ramos, Fábio Pittella Silva & Diêgo Madureira Oliveira. (2019) Long‐term in vitro treatment with telomerase inhibitor MST‐312 induces resistance by selecting long telomeres cells. Cell Biochemistry and Function 37:4, pages 273-280.
Crossref
Crossref
Hee-Sheung Lee, Mar Carmena, Mikhail Liskovykh, Emma Peat, Jung-Hyun Kim, Mitsuo Oshimura, Hiroshi Masumoto, Marie-Paule Teulade-Fichou, Yves Pommier, William C. Earnshaw, Vladimir Larionov & Natalay Kouprina. (2018) Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy. Cancer Research 78:21, pages 6282-6296.
Crossref
Crossref
Cagatay Günes, Felix Wezel, Jennifer Southgate & Christian Bolenz. (2018) Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nature Reviews Urology 15:6, pages 386-393.
Crossref
Crossref
Meng-Ying Liu, Ashley Nemes & Qi-Gang Zhou. (2018) The Emerging Roles for Telomerase in the Central Nervous System. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Fatma Dogan & Cigir Biray Avci. (2018) Correlation between telomerase and mTOR pathway in cancer stem cells. Gene 641, pages 235-239.
Crossref
Crossref
Graziella Cimino-Reale, Paolo Gandellini, Francesca Santambrogio, Marta Recagni, Nadia Zaffaroni & Marco Folini. (2017) miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an “ALT-like” phenotype in diffuse malignant peritoneal mesothelioma cells. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Theresa Vasko, Andrea Kaifie, Matthias Stope, Thomas Kraus & Patrick Ziegler. (2017) Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions. International Journal of Molecular Sciences 18:11, pages 2267.
Crossref
Crossref
Chiara Pesenti, Leda Paganini, Laura Fontana, Emanuela Veniani, Letterio Runza, Stefano Ferrero, Silvano Bosari, Maura Menghi, Giovanni Marfia, Manuela Caroli, Rosamaria Silipigni, Silvana Guerneri, Silvia Tabano & Monica Miozzo. (2017)
Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and
IDH1
,
IDH2
, and
TERT
mutation status
. Oncotarget 8:34, pages 57134-57148.
Crossref
Crossref
Karollyne S. Morais, Ana Flávia R. Guimarãesb, Doralina A.R. Ramos, Fábio P. Silva & Diêgo M. de Oliveira. (2017) Long-term exposure to MST-312 leads to telomerase reverse transcriptase overexpression in MCF-7 breast cancer cells. Anti-Cancer Drugs 28:7, pages 750-756.
Crossref
Crossref
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu, Kaori Suzuki, Kuniaki Saito, Keiichi Kobayashi, Fumi Higuchi, Takeo Uzuka, Ryohei Otani, Kaoru Tamura, Kazutaka Sumita, Makoto Ohno, Yasuji Miyakita, Naoki Kagawa, Naoya Hashimoto, Ryusuke Hatae, Koji Yoshimoto, Naoki Shinojima, Hideo Nakamura, Yonehiro Kanemura, Yoshiko Okita, Manabu Kinoshita, Kenichi Ishibashi, Tomoko Shofuda, Yoshinori Kodama, Kanji Mori, Yusuke Tomogane, Junya Fukai, Koji Fujita, Yuzo Terakawa, Naohiro Tsuyuguchi, Shusuke Moriuchi, Masahiro Nonaka, Hiroyoshi Suzuki, Makoto Shibuya, Taketoshi Maehara, Nobuhito Saito, Motoo Nagane, Nobutaka Kawahara, Keisuke Ueki, Toshiki Yoshimine, Etsuo Miyaoka, Ryo Nishikawa, Takashi Komori, Yoshitaka Narita & Koichi Ichimura. (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications 4:1.
Crossref
Crossref